1/46
Looks like no tags are added yet.
Name | Mastery | Learn | Test | Matching | Spaced | Call with Kai | Chat |
|---|
No analytics yet
Send a link to your students to track their progress
Familial adenomatous polyposis (FAP)
Gene: APC
Adenomatous Colon Polyps
100s-1000s (“carpeting”)
Onset 10-15yo
Inheritance
Autosomal Dominant
Inherited 70%
De Novo 30%
Clinical Features
GI
Adenomatous colon polyps: Colon + Duodenum
Onset ***10-15yo****
Stomach
Fundic gland polyps
Extra Intestinal Features
Eye
Congenital Hypertrophy of the Retinal Pigment Epithelium (CHRPE)
Bone
Osteomas: skull, mandible, long bones
Dental abnormities (extra/missing teeth)
Desmoid tumors
FAP: Cancer Risk + Management
Cancer Risk
Colorectal: 100%
Duodenal 4-12%
PAPILLARY thyroid
Pancreatic
Hepatoblastoma
Medulloblastoma (Turcot syndrome)
Management
Colon
Colonoscopy
start 10-12 yo
every 1-2 years
Upper GI
Upper endoscopy
start 20-25 yo
Thyroid
Thyroid ultrasound
Annual
start Teens-early adulthood
Attenuated FAP
Gene: APC
Variants near the 5′ end, 3′ end, or portions of exon 9 are more often associated with attenuated FAP
REDUCED PENETRANCE
REDUCED SEVERITY
Clinical Features
20–100 adenomas (later onset)
CRC develops later (often 50s–60s)
Right-sided colon predominance is common
Management
Colonoscopy: begin in late teens -20s
Upper GI endo.: yes
Thyroid surveillance: Yes
MUTYH -Polyposis
Gene: MUTYH
10-100 Adenomatous colon polyps (like aFAP)
****SERRATED adenomas***
Inheritance
Autosomal RECESSIVE
***SINGLE MUTYH carriers: no MAP or polypsis, small increas in CRC risk***
Clinical Features
Colon polyps
Colorectal
Duodenal
Cancer Risk
CRC 70-90%
Duodenum (not as high as FAP)
Ovarian
Bladder
MUTYH -Polyposis: Management
Colon
Colonoscopy
Start 25-30yo
every 1-2 years
Upper GI
Upper endoscopy
Start 30-35yo
Juvenile Polyposis Syndrome
Gene: SMAD4, BMPR1A
HAMARTOMATOUS ( colon polpys (highly variable number
Clinical criteria: AT LEAST 5 juv. polyps in colon
juvenile = subtype of hamartomatouss
Inheritance
Autosomal Dominant
De Novo 50%
Inherited 50%
Clinical Features
Colon
Harmartomaus (juvenile type) polyps
Onset 10-20yo
RECTAL BLEEDING
*****SMAD4 Variant****
Hereditary Hemorgric Telangiectasia (AVMs, telangiectasias, epitaxis)
Juvenile Polyposis Syndrome: Managment
Surveillance
Colon
Colonoscopy
Start 12-15 yo
Every 1-3 years
Upper Gi
Upper endoscoypu
Start 12-15 yo
every 1-3
SMAD4 variant
More upper GI surveillance
HHT screening (full body imaging looking for AVMs)
Peutz-Jegher Syndrome
Gene: STK11
HAMARTOMATOUS ( colon polpys (highly variable number
Peutz-Jeghers polyp = sub type of hamartomatous p
Inheritance
Autosomal Dominant
De Novo 50%
Inherited 50%
Clinical Features
GI
DOZENS Hamartomatous polyps (peutz-jeghers subtype)
Onset 10-20
Throughout GI tract (but small intestine especially)
*****INTUSSUSCEPTION**** (Hallmark) GI tract folds in on itself
Skin
****Mucocutaneous Pigmentation **** (dark blue-brown macules) HALLMARK
Mouth
Face
Fingers/Toes
Other
****MALES: Gynomastia****
Peutz-Jegher Syndrome: Cancer Risk
Cancer Risk
GI
Colorectal:35-30%
Gastric 25-30%
Small Bowel 30-35%
****PANCREATIC 30-35%****
GYN/Gonads
Breast: 45-55%
Ovary (Sex cord tumor)
MALES: Large-cell Calcifying Sertoli cell tumor → cause GYNOMASTIA
Peutz-Jegher Syndrome: Managment
Surveillance
GI
Full colon, stomach small bowel:
Colonoscopy
Upper endoscopy
Small bowel evaluation (capsule endoscopy or MR enterography)
Start 8yo
polyp present: every 1-3 years
No polyp present: resume at 18yo (2-3yrs)
Pancreas
MRI or Endoscopic Ultrasound
Start 30-35yo
Annual
Breast
Clinical Breast exam: at 25yo, ever 6-12months
Annual Breast MRI: start 25yo
Annual mammography: start 30yo
Lynch syndrome: Overview
Gene: MLH1, MSH2, MSH6, PMS2, EPCAM
Adenomous Polyps: Less than 10 (Right Sided)
Inheritance
Autosomal Dominant
Clinical Features
Colon
Adenotmous Polyps: 10 or fewer
Cancer Risk
GI
Colorectal (right sided):
MLH1, MSH2: 40-80%
Lower for MSH6, PMS2, EPCAM
Stomach
Small bowel
Pancreas
GYN/
***Endometrial*** (can occur BEFORE CRC)
MSH6: 40-60% (highest)
Ovarian: 10-20%
Prostate
OTHER
Brain: Glioblastoma (Turcot)
Skin: Sebaceous adenomas (Muir-Torre)
Lynch syndrome: Managment
Surveillance
Colon
Colonsocpy
MLH1/MSH2/EPCAM: start 20-25yo
MSH6/PMS2: Start 30-35yo
Repeat 1-2 years
Gastric
Upper endoscopy
especially MLH1/MSH2
Start 30-40yo
Every 2-4 years
Endometrial
Endometrial Biopsy
CONSIDERED starting at 30-35yo
especially MLH1, MSH2, MSH6
every 1-2 years
Ovarian
Risk Reducing Surgery
Total hysterectomy
Bilateral Salpingo-oophorectomy (BSO)
After childbearing (post menopause)
Lynch syndrome: Suggestive Pathology
Immunohistochemistry of tumor
MLH1 and PMS2 missing → MLH1 germline
MODIFER: check MLH1 hypermethylation
MODIFER: if BRAF also missing cancer is SPORDAIC
Only PMS2 missing → PMS2 germline
MSH2 and MSH6 missing → MSH2 germline
Only MSH6 missing → MSH6 germline
Satellite Instability
High microsatellite instability → defective DNA mismatch repair
Amsterdam II Criteria
More than 1 Lynch syndrome cancer dx under 50yo
2 Successive generations affected
More than 3 family members affected with lynch-related cancers
1 member must be first degree with the other two
Lynch syndrome: Murie-Torre
Muire-Torre Syndrome
Lynch syndrome +
Sebaceous adenomas
Keratoacanthomas
Usually MSH2
Lynch syndrome: Constitutional Mismatch Repair Deficiency (CMMRD)
Gene: MLH1, MSH2, MSH6, PMS2, EPCAM
Childhood cancer predisposition syndrome
Inheritance
Autosomal Recessive
Clinical Features
Skin
****Cafe-au-Lait Macules**** (like NF1) HALLMARK
GI
Multiple adenomas - Childhood:
***Polyposis can be extensive****
Childhood Cancer (100% before 18yo)
Brain
Glioblastomas
Hematologic
Leukemia
Lymophoma
“Typical” Lynch syndrome Cancers
Endometrial cancer
Ovarian cancer
Gastric cancer
Urinary tract cancers
Constitutional Mismatch Repair Deficiency (CMMRD): Managment
Surveillance
Colon
Colonoscopy
Start at 6yo
repeat 6-12months
Upper GI
Upper endoscopy
Start 8-10yo
Annual
Brain
Brain MRI
Start infancy or early childhood
repeat 6-12 months
Complete Blood Count (CBC)
Every 6 months
Tip for Fam Hx of colon Cancer
Asses age of diagnosis
If much later than 35yo, less likely to be FAP
If nobody else affected → think MUTYH (AR)
If no polyps found → rule out polyposis syndromes
. Hereditary breast and ovarian cancer syndrome: BRCA2 type
Gene: BRCA2
Breast , less ovarian than BRCA1 + Prostate, PANCREATIC, male breast, melanoma
Inheritance
Autosomal Dominant
Biallelic = Fanconi Anemia
Clinical Features
Breast Cancer: 83% risk
***ER + PR positive / HER 2 Negative***
Onset 40-50s yo
Ovarian Cancer: 27%
High-grade serous carcinoma
later onset than BRCA1
Other Cancers (much higher than BRCA1)
****Male Breast Cancer: 9%****
****Pancreatic: 7%*****
Melanoma
Prostate: 20%
Hereditary breast and ovarian cancer syndrome: BRCA1 type
Gene: BRCA1
Breast and Ovarian Cancer: early onset, triple-negative, aggressive
Inheritance
Autosomal Dominant
Clinical Features
Breast Cancer: 87% lifetime risk (2nd primary 83%)
Triple Negative (ER/PR/HER2 negative)
Onset 30-40s yo
Bilateral common + contralateral risk increased
Ovarian Cancer: 63% lifetime risk
High-grade serous carcinoma
Onset 40-50s yo
Other Cancers
Male Breast ca: 1%
Prostate: 8%
Pancreatic
BRCA2 Management
Surveillance
Breast (same as BRCA1)
Annual MRI
Start at 25yo
MRI + Mammography
Start at 30yo
Clinical Breast Exam
Start 25yo
Every 6-12 months
CONSIDER Prophylactic Bilateral Mastectomy (risk not 0% though)
Ovary
Risk reducing bilateral salpingo-oophorectomy
at 40-45yo (later than BRCA1)
Pancreatic
MRCP (Cholangiopancreatography)
and/or
Endoscopic Ultrasound
Start at 50yo OR 10 years younger than earliest Pancreatic cancer in the family
Prostate
Annual PSA test
Start at 40yo
Chemoprevention
More effective than with BRCA1 b/c Estrogen Receptor positive breast cancer
Tamoxifen: blocks estrogen receptor and prevents RECEPTOR PSOTIVE breast cancer
Aromatase inhibitors (POST-MENOPAUSE)
Anastrozole
Exemestane
BRCA 1 Management
Surveillance
Breast
Annual MRI
Start at 25yo
MRI + Mammography
Start at 30yo
Clinical Breast Exam
Start 25yo
Every 6-12 months
CONSIDER Prophylactic Bilateral Mastectomy (risk not 0% though)
Ovary
Risk reducing bilateral salpingo-oophorectomy
at 35-40yo
Chemoprevention
Chemoprevention less effective than in BRCA2
Tamoxifen: blocks estrogen receproti and prevents RECEPTOR PSOTIVE breast cancer
HBOC syndrome: Testing considerations
Genetic Testing
10-15% of variants are due to GENOMIC REARRANGEMNTS
if someone says they tested negative for BRCA1/2 → MAKE SURE rearrangements were included
Ashkenazi Jewish Ancestry
1/40 with AJ ancestry have founder mutations
3 AJ founder mutations
Offer AJ ancestry screening EVEN IF they are testing for a know-familial variant
Li Fraumeni Syndrome
Gene: TP53
Childhood Cancer Syndrome
Big 5: Adrenocortiol carcinoma, Breast, Leukemia, Sarcoma, Brain/CNS tumors
Inheritance
Autosomal dominant
Inherited 80%
De Novo 20%
Clinical Features
Breast Cancer
HER2 or ER positive
Onset 20-40s yo
Soft tissue Sarcomas
Leiomyosarcoma, Liposarcoma Rhabdomyosarcoma
Childhood onset
Osteosarcoma
Childhood-adolescence onset
Brain Tumors
Astroctoma, Glioblastoma, Medulloblastoma
****Adrenocortical Carcinoma****
Onset before 5yo
Leukemia
Acute Leukmeia
Li Fraumeni: Recomdneaitons
AVOID UV/Radiation exposure → very susceptible to inducing cancer
Surveillance
Breast
Clinical exam
start 20-25yo
Every 6-12 months
Annual Breast MRI
start 20-25yo
Annual Mammography
Start 20-25yo
Colon
Colonoscopy
Start 25yo
Every 2-5 years
Risk Reduction
Bilateral Mastectomy
Discuss reproductive options :
IVF and PGT
Fanconi Anemia
Genes: BRCA1, BRCA2, PALB2, BRIP1
Birth defects + Pancytopenia + Leukemia
Inheritance
Autosomal Recessive
Clinical Features
Skeletal/Other
Bone Marrow Failure (onset 5-10yo)
***Radial Ray Defects: absent thumb, absent radius (at birth) ****
Short Stature
Microcephaly
Cafe-Au-Lait spots
Cancer
***Acute Myeloid Leukemia***
Onset Teenage years
Head and Neck Squamous Cell Carcinoma
Gynecologic Squamous Cell Carcinoma
Gene-specific cancer risk
ex: BRCA1 → Breas/Ovarian
Management
Testing Strategy
****Chromosome Breakage Analysis****
PTEN-hamartoma tumor syndrome
Gene: PTEN
Umbrella Term: cover Cowden, Bannayan-Rilet-Ruvalcaba, Proteius-like syndrome (but just focus on Cowden)
Big Head – Benign Growths – Breast/Thyroid/Endometrium
Inheritance
Autosomal Dominant
Inherited 80%
De Novo 20%
Clinical Features
Developmental
****Macrocephaly****
***Autism***
Developmental Delay
Hamartomas (benign overgrowths)
****Hamartomous GI polyps****
usually 10-50
Lipomas
Fibromas
Skin
Mucocutaneus Lesions (HALLMARK)
****Trichilemmomas (face)*****
Oral papilloma
Acral Keratoses
Cancer
Breast: 67-85% Risk
ER positive
Thyroid: 20-35% Risk
***Follicular*** thyroid carcinoma
Endometrial: 20-30% Risk
Renal Cell Carcinoma: 30-35% Risk
Cowden Sydnrome: Manamgnet
Surveillance
Breast
Clinical Breast Exam
Start 25yo
Every 6-12 months
Annual Breast MRI
Start 30yo
Annual Mammography
Start 30yo
Thyroid
Annual Thyroid Ultrasound
*****Start 7yo****
Kidney
Renal Ultrasound
Start 40yo
Repeat every 1-2 years
Breast/Ovarian Cancer Referral Criteria (HBOC)
Age
Any Breast Ca <50yo
***Triple-Negative Breast ca.<60yo***
Type:
Any Male Breast Ca.
Any Ovarian Ca. (especially high-grade serous)
Pancreatic w/ HBOC fam hx
Metastatic Prostate
Family Hx
One 1st degree w/ Any Breast Ca <50yo
Two relative (same sidE) w/ Breast Ca (ANY AGE)
Three HBOC assoacted Ca. on one side of the family (ANY AGE)
Ashkenazi Jewish Acnestry
One HBOC-assoacited cancer (lower threshold)
Bloom Syndrome
Gene: BLM
Chromosome Breakage Syndrome: detected with sister chromatid exchange assay
Small Stature + Sun Sensitivity + Cancer
Inheritance
Autosomal Recessive
Clinical Features
Growth/Development
Intrauterine growth restriction
Proportionate Short Stature (Unlike Russell-Silver syndrome)
Immunodeficney (Recurrent Infections)
Fertility
Men infertile
Women early menopause
Skin
Photosensitive Rash
occurs with TELANGIECTASIAS
Cancer (extremely broad)
Leukemia (childhood onset)
Lymphoma
CRC: 20-30s yo
Breast
Skin
Werner Syndrome
Gene: WRN
Chromosome Breakage Syndrome
Inheritance
Autosomal Recessive
Clinical Features
Progeria
Normal Childhood → failure to have puberty growth spurt
Premature again start 20-30s: Greying, hair loss, ****BILATERAL CATRACTS***, osteoporosis, diabetes, atherosclerosis (heart deisease)
Cancer
Thyroid Cancer
Soft tissue Sarcoma
Osteosarcoma
Melanoma
Colorectal Cancer Referral: Lynch
Age
CRC <50yo
Endometrial <50yo
Type
Multiple Lynch Cancers in one person
Colon + endometrial
Colon + ovarian
Family Hx (Amsterdam II Criteria - 3-2-1)
3 Relatives with a Lynch Ca
2 Generations
1 Diagnosed <50yo
Somatic testing
Loss of IHC in PMS2, MSH6, MLH1 w/PMS2, MSH2 w/MSH6
MSI-High
Ataxia-Telangiectasia
Gene: ATM
Chromosome Breakage Syndrome
Ataxia + Tiny Blood Vessels + Infections
AVOID RADITION
Inheritance
Autosomal Recessive
Clinical Features
Progressive Cerebellar Ataxia
Onset 1-4 yo
Peripheral Neuropathy also develops over time
Telangiectasia: dilated superficial blood vessels
Onset 3-6yo
Immunodeficney
recurrent infections: Pneumonia, Ear, Sinus
Cancer Risk
Leukemia (childhood)
Lymphoma
****Breast Cancer (ONLY FOR HETEROZYGOTES)****
Laboratory Findings
***Elevated Alpha-Fetoprotein**** AFTER BIRTH
Colon Polyps Referral
# of Polyps
>100 Adenomas
FAP
10-100 Adenomas
Attenuated FAP
MUTYH
10-19:
Consider testing
1-9
probably sporadic
Type of Polyps
>5 Juvenile (HAMARTOMATOUS)
Juvenile Polyposis
Any Peutz-Jeger (HAMARTOMATOUS)
Peutz-Jegers Syndrome
>20 Serrated Polyps
Serrated Polyposis
>5 LARGE serrated polyps (near anus)
Serrated Polyposis
CHEK2- Associated Hereditary Cancer
Gene: CHEK2
Breast and Colon → NO OVARIAN
Inheritance
Autosomal Dominant
Clinical Features
Breast Cancer: 20-40% lifetime risk
Er-positive
Onset 40-60s yo
****Colorectal Cancer: UPDATED****
CRC risk no longer elevated
Prostate: Modest risk increase
Surveillance
Breast
Annual Mammography
start at 40yo
Annual Breast MRI
start 30-35yo
Clinical Breast Exam
Every 6-12 months
PALB2-Assoacited HBOC
Gene: PALB2
BRCA2 phenotype WITH OUT OVARIAN CANCER → Pancreatic the big one
Bialleic = Fanconi Anemia, Complementation gorup N (FANCN)
Inheritance
Autosomal Dominant
Clinical Features
Breast Cancer: 35-55% risk
ER-positive/ HER-2 Negative
Onset 40-50s yo
Pancreatic Cancer: 5%
Surveillance
Breast
Annual Breast MRI
Start at 30yo
Annual Mammography
Start at 30yo
Pancreatic
***Need at least one 1st degree relative with Pancreatic Ca***
Annual MRI or EUS
Start at 50yo (or 10 years before ealriest Pan. Ca. in family)
Pancreatic Screening
STK11, BRCA2, CDKN2A → pancreatic screening regardless of family history.
PALB2, BRCA1, and Lynch → pathogenic variant + family history.
Hereditary Diffuse Gastric Cancer
Gene: CDH1, CTTNA1 (rare)
DIFFUSE gastric cancer: no single discrete mass
Inheritance
Autosomal Dominant
Clinical Features
Gastric Cancer
****Signet Ring Cell Carcinoma**** (HALLMARK)
Onset 30-50s yo
Breast Cancer: 42% risk
****LOBULAR breast Cancer ****(Hallmark)
ER Positive
***Bilateral or multifocal***
Management
Stomach
Surveillance Endoscopy NOT Effective → cancer too diffuse
Prophylactic Total Gastrectomy
at 20-30yo
Breast
Clinical Breast Exam
Start 25yo
every 6-12 months
Annual Breast MRI
Start 30yo
Annual Mammography
Start 30yo
Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS)
Gene: APC
NOT in coding region → n the PROMOTOER 1B
Colon usually normal or few polyps
Inheritance
Autosomal Dominant
Clinical Features
Stomach
100-1000s of Fundic Gland Polps
*****Gastric Adenocarcinoma**** (cancer)
Surveillance
Stomach
Upper Endoscopy
Start late teens-early 20s
Every 1-2 years
Consider Gastrectomy if really bad
Hereditary Paraganglioma–Pheochromocytoma Syndrome (HPPS)
Gene: SDHB, SDHD , SHD_
SDH-Dad: must be inherited from DAD to cause disease
SDH-Bad: higher metastasis and mortality
Inheritance
Autosomal Dominant
Clinical Features
Neuroendocrine cancers in two types
Paraganglioma (form within Adrenal gland - on top of kidney)
secrete catecholamines
headaches, sweating, palaipations
Pheochromocytoma (form OUTSIDE the adrenal gland)
Head & Neck, Chest, Abdomen, Pelvis
DO NOT secrete catecholamines
Onset 20-50yo
Management
Surveillance
MRI of neck to Pelvis
Start 10-15 years
Every 2-3 years
Annual Blood pressure + Blood/IUrine check
Detect Metanephrines
Multiple Endocrine Neoplasia Type I (MEN1)
Gene: MEN1
3 P’s: Pituitary, Parathyroid, Pancreas
Inheritance
Autosomal Dominant
Clinical Features
Adenomas that increase hormones
Pituitary
Prolactin (women), Growth hormone, ACTH
Parathyroid
Hyperparathyroidism
“"Stones, Bones, Groans, Thrones, and Psychiatric Overtones”
***Hypercalcemia**
Pancreatic
Management
Surveillance
Pituitary
Annual Prolactin, IGF-1
Start at 5yo
MRI
every 3-5 years
Parathyroid
Annual Calcium, PTH
Start at 8yo
Pancreas
MRI or EUS
Start 10-20yo
Every 1-3 years
Treatment
Parathyroidectomy treats Hyperparathyroidism
Multiple Endocrine Neoplasia Type II A (MEN2A)
Gene: RET
RET gain of function → uncontrolled proliferation of neuroendocrine cells
MEN2A = Parathyroid + Adrenal + Thyroid
Inheritance
Autosomal Dominant
Clinical Features
Thyroid
***MEDULLARY Thyroid Carcinoma***: 95% risk
Onset: Early Adulthood
Adrenal
Pheochromocytoma (usually BENIGN ie. non-metastatic)
Parathyroid
Hyperplasia → *** PRIMARY HYPERPARATHYROIDISM ***
NO CANCER
Management
Adrenal
Annual Plasma Metanephrines
Start 11-16 yo
Parathyroid
Annual Calcium, PTH
Start adolescence - early adulthood
Thyroid
PROPHYLATIC THYROIDECTOMY (lifesaving)
at 5yo (Variant Dependent - could be later)
Multiple Endocrine Neoplasia Type IIB (MEN2B)
Gene: RET
Marfanoid Habitus w/ Medullary and Pheochromocytoma
Inheritance
Autosomal Dominant
****DE NOVO 50%****
Clinical Features
NO HYPERTHYROIDISM (unlike MEN2A)
Thyroid
***Medullary Thyroid Carcinoma****
Onset EARLY CHILDHOOD
VERY AGGRESSIVE
Adrenal
Pheochromocytoma
Mouth
***Mucosal Neuromas***(HALLMARK): Lips + Tongue
Marfanoid Habitus
But NO aortic aneurysm
Management
Thyroid
PROPHYLATIC THYROIDECTOMY (lifesaving)
***Within 1st Year of Life****
Adrenal
Annual Plasma Metanephrines
Start EARLIER than MEN2A
Parathyroid
Annual Calcium, PTH
Start EARLIER than MEN2A
Von Hippel-Lindau syndrome
Gene: VHL
Hemanioblastomas, Clear cell Renal Cell Carcinoma, Pheochromocytoma
Brain - Kidney - Adrenal
Eye→ Brain→ Kidney progression
Inheritance
Autosomal Dominant
Inherited 80%
De Novo 20%
Clinical Features
CNS
Hemangioblastomas
Brain / Spinal chord: onset 20-30s yo
***RETINA****: onset 5-15yo, often first manifestation
Kidney
Clear Cell Renal Cell Carcinoma (leading cause of mortality
Bilateral
Multi Focal
Onset 30-50yo
Renal Cysts
Adrenal
Pheochromocytoma
Bilateral
Onset childhood
Management
Surveillance
Eye exam: by 1yo
Plasma Metanephrines: stat 5yo
Brain MRI: Start 11-15yo
Familial atypical multiple mole melanoma syndrome
Gene: CDKN2A
Inheritance
Autosomal Dominant
Clinical Features
Skin
Moles (dozens, usually >50)
Onset childhood-adolescence
Melanoma
Onset 20-40s yo
Pancreas
****Pancreatic Cancer***: 15-20% risk
Surveillance
Skin Exam: every 6-12months
Start childhood (10yo)
Pancreas
MRI or EUS
Start 40yo
Gorlin Syndrome
Gene: PTCH1, SUFU
Nevoid Basal Cell Carcinoma
Cancer risk: MEDULLOBLASTOMA
Inheritance
Autosomal dominant
Inherited 80%
De Novo 20%
Clinical Features
Cancer
Basal Cell Carcinomas
100s over lifetime
Onset before 20yo
***Medulloblastoma***
SUFU: 20-30%, onset before 5yo
PTCH1: <2%
Skeletal
***Jaw Cysts*** (Odontogenic Keratocysts)
Mandible
Tooth displacement
Onset childhood-Adolescence
Random Skeletal: Fused ribs, Scolosis, vertabrae anaomlies
Craniofacial
Macrocephaly
Frontal Bossing
Surveillance
PTCH1: no routine Brain MRI
SUFU: Brain MRI
every 3-4 months until 3yo
every 6 months until 5yo
Xeroderma Pigmentosum
Gene: many genes -
nucleotide excision repair (NER) genes
Extremely susceptible to UV-induced skin cancer
Inheritance
Autosomal Recessive
Clinical Features
Skin
Extreme Photosensitivity (skin and eyes)
Freckling before 2yo
Skin Cancers before 10yo
BCC, SCC, Melanoma
Eye
Loss of eye lashes
Vision Loss
Eye cancer
CNS (30%)
Progressive hearing loss
Ataxia
Seizures
Birt-Hogg-Dube Syndrome
Gene: FLCN
Skin, Lungs, Kidney
Inheritance
Autosomal Dominant
Clinical Features
Skin
***Fibrofolliculomas***: benign hair follcile tumors
Face, Neck, Upper trunk
Onset 20-40s yo
Melanoma
Lung
Pulmonary Cysts
Bilateral
Onset 20-40s yo
Spontaneous Pneumothorax
Onset 20-40s yo
Kidney
Renal Cell Carcinoma
Bilateral
Multifocal
***Slow growing***
Onset 40-60yo
Management
Kidney
MRI or CT
Start 20yo
Every 1-2 year
Lung
Baseline chest CT